Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab

NCT03212651 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]